CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Friday.

Other equities research analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $2.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th. Maxim Group reiterated a “buy” rating and set a $4.00 target price on shares of CASI Pharmaceuticals in a research report on Friday, September 8th.

Shares of CASI Pharmaceuticals (NASDAQ:CASI) traded up 15.38% during mid-day trading on Friday, hitting $1.50. 355,943 shares of the stock were exchanged. CASI Pharmaceuticals has a 52 week low of $0.91 and a 52 week high of $1.76. The stock’s 50-day moving average is $1.02 and its 200-day moving average is $1.12. The stock’s market capitalization is $90.29 million.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Analysts forecast that CASI Pharmaceuticals will post ($0.15) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/15/casi-pharmaceuticals-inc-casi-stock-rating-upgraded-by-valuengine.html.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.